At this time, Edarbi (azilsartan) is not available in generic form, despite the fact that the first patent for the drug has expired. Although azilsartan is considered the generic name for Edarbi, it is not a generic version of the drug.
Edarbi™ (azilsartan medoxomil) is a prescription medication used to treat high blood pressure, known medically as hypertension. It belongs to a class of medications called angiotensin II receptor blockers, or ARBs for short.
Edarbi is made by Takeda Pharmaceuticals America, Inc. It is currently under the protection of a patent that prevents any generic Edarbi from being manufactured in the United States.
The first patent for Edarbi expired in June 2012. Yet, no generics are available yet. This suggests that at least one later-expiring patent is still protecting the drug from generic competition. The next patent for Edarbi is set to expire in December 2013. This is the earliest predictable date that a generic version could become available.
However, other circumstances could come up to extend or shorten this exclusivity period. This could include such things as lawsuits or other patents for specific Edarbi uses. Once the patent expires, there may be several companies that manufacture a generic Edarbi drug.
No -- azilsartan is the active ingredient in Edarbi, but is not a generic version of it. What can be confusing is that the active ingredient of a drug is often referred to as the "generic name."
The generic name is different from a generic version of a medicine. In order for there to be a generic version, the original medicine must have gone off-patent and another company besides the original manufacturer must make the product.